6:09 AM
 | 
Jun 08, 2018
 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing one ordinary share.

At the $16 midpoint, Autolus would raise $125 million and would be valued at $604.4 million. Underwriters are Goldman Sachs, Jefferies, Wells Fargo and William Blair.

Autolus' pipeline includes four programmed T cell...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >